Trials / Unknown
UnknownNCT03793205
G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients
Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Lei Li · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients. Patients all accepted platinum-based chemotherapy 3-4 weeks once per course. The primary end is the incidence of FN in every course of chemotherapy. After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Long-acting G-CSF | Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required. |
| DRUG | Short-acting G-CSF | Short-acting G-CSF will be given as required 24 hours after the chemotherapy. |
Timeline
- Start date
- 2019-01-03
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
- First posted
- 2019-01-04
- Last updated
- 2019-01-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03793205. Inclusion in this directory is not an endorsement.